Article information
Full text is only aviable in PDF
Bibliografía
[1.]
Cystic Fibrosis Foundation.
Patient Registry Annual Data Report 1999.,
[2.]
M.E. Hodson.
Treatment of cystic fibrosis in the adult.
Respiration, 67 (2000), pp. 595-607
[3.]
Fundacion Sira Carrasco para la ayuda a la fibrosis quistica.
Encuesta patogenos multirresistentes y fibrosis quistica, (2000),
[4.]
J. Borowsky, K. Kamienska, I. Rutecka.
Methicillin-resistant staphylococcii.
Br Med J, 1 (1964), pp. 983
[5.]
M.R. Jacobs, H.J. Koornhof, R.M. Robins-Browne, C.M. Stevenson, Z.A. Vermaak, I. Freiman, et al.
Emergence of multiply resistant pneumococci.
N Engl J Med, 299 (1978), pp. 735-740
[6.]
R.E. Hancok, D.P. Speert.
Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and impact on treatment.
Drug Res Updates, 3 (2000), pp. 247-255
[7.]
P.M. Beringer, M.D. Appleman.
Unusual respiratory bacterial flora in cystic fibrosis: microbiologic and clinical features.
Curr Op Pulm Med, 6 (2000), pp. 545-550
[8.]
B. Giwercman, P. Lambert, V.T. Rosdahl, G.H. Shand, N. Hoiby.
Rapid emergence of resistance in Pseudomonas aeruginosa in cystic fibrosis patients due to in-vivo selection of stable partially derepressed. β-lactamase producing strains.
J Antimicrob Chemother, 26 (1990), pp. 247-259
[9.]
S. Ballestero, A. Fernandez-rodriguez, R. Villaverde, H. Escobar, J.C. Perez-Diaz, F. Baquero.
Carbapenem resistance in Pseudomonas aeruginosa from cystic fibrosis patients.
J Antimicrob Chemother, 38 (1996), pp. 39-45
[10.]
T. Kohler, M. Michea-Hamzehpour, S.F. Epp, J.C. Pechere.
Carbapenem activities against Pseudomonas aeruginosa: respective contributions of OprD and efflux systems.
Antimicrob Agents Chemother, 43 (1999), pp. 424-427
[11.]
S. Westbrock-Wadman, D.R. Sherman, M.J. Hickey, S.N. Coulter, Y.Q. Zhu, P. Warrener, et al.
Characterization of a Pseudomonas aeruginosa efflux pump contributing to aminoglycoside impermeability.
Antimicrob Agents Chemother, 43 (1999), pp. 2975-2983
[12.]
S. Jalal, O. Ciofu, N. Hoiby, N. Gotoh, B. Wretlind.
Molecular mechanisms of fluoroquinolone resistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
Antimicrob Agents Chemother, 44 (2000), pp. 710-712
[13.]
R.A. Howe, R.C. Spencer.
Macrolides for the treatment of Pseudomonas aeruginosa infections?.
J Antimicrob Chemother, 40 (1997), pp. 153-155
[14.]
A. Alonso, E. Campanario, J.L. Martinez.
Emergence of multidrugresistant mutants is increased under antibiotic selective pressue in Pseudomonas aeruginosa.
Microbiology, 145 (1999), pp. 2857-2862
[15.]
K. Poole, K. Krebes, C. McNally, S. Neshat.
Multiple antibiotic resistance in Pseudomonas aeruginosa: evidence for involvement of an efflux operon.
J Bacteriol, 175 (1993), pp. 7363-7372
[16.]
A. Oliver, R. Canton, P. Campo, F. Baquero, J. Blazquez.
High-frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection.
Science, 288 (2000), pp. 1251-1253
[17.]
T.F. Ah, G.A. O'Toole.
Mechanisms of biofilm resistance to antimicrobial agents.
Trends Microbiol, 9 (2001), pp. 34-39
[19.]
R. Canton, A. Oliver, F. Baquero.
Microbiologia de las vias respiratorias en la fibrosis quistica.
Fibrosis quistica, atencion integral, manejo clinico y puesta al dia, pp. 105-158
[20.]
J.M. Blondeau, G.S. Tillotson.
Antimicrobial susceptibility patterns of respiratory pathogens. A global perspective.
Semin Respir Infect, 15 (2000), pp. 195-1207
[21.]
L.V.M. Moller, A.G. Regelink, H. Grasselier, J. Dankert, L. Van Alphen.
Antimicrobial susceptibility of Haemophilus influenzae in the respiratory tracts of patients with cystic fibrosis.
Antimicrob Agents Chemother, 42 (1998), pp. 319-324
[22.]
J. Campos, F. Roman, M. Georgiou, C. Garcia, R. Gomez-Lus, R. Canton, et al.
Long-term persistence of ciprofloxacin-resistant Haemophilus influenzae in patients with cystic fibrosis.
J Infect Dis, 174 (1996), pp. 1345-1347
[23.]
A. Fenoll, I. Jado, D. Vicioso, A. Perez, J. Casal.
Evolution of Streptococcus pneumoniae serotypes and antibiotic resistance in Spain: Update (1990-1996).
J Clin Microbiol, 36 (1998), pp. 3447-3454
[24.]
P.H. Gilligan.
Microbiology of airway disease in patients with cystic fibrosis.
Clin Microbiol Rev, 4 (1991), pp. 35-51
[25.]
R. Canton, M.I. Morosini, S. Ballestero, M.E. Alvarez, H. Escobar, L. Maiz, et al.
Lung colonization with Enterobacteriaceae producing extended spectrum beta-lactamases.
Pediatr Pulmonol, 24 (1997), pp. 213-217
[26.]
M. Lecso-Bornet, J. Pierre, D. Sarkis-Karam, S. Lubera, E. Bergogne- Berezin.
Susceptibility of Xanthomonas maltophilia to six quinolones and study of outer membrane proteins in resistant mutants selected in vitro.
Antimicrob Agents Chemother, 36 (1992), pp. 669-671
[27.]
A. Alonso, J.L. Martinez.
Multiple antibiotic resistance in Stenotrophomonas maltophilia.
Antimicrob Agents Chemother, 41 (1997), pp. 1140-1142
[28.]
M. Denton, K.G. Kerr.
Microbiology and clinical aspects of infection associated with Stenotrophomonas maltophilia.
Clin Microbiol Rev, 11 (1998), pp. 57-80
[29.]
S. Valdezate, A. Vindel, E. Loza, F. Baquero, R. Canton.
Antimicrobial susceptibilities of unique Stenotrophomonas maltophilia.
Antimicrob Agents Chemother, 45 (2001), pp. 1581-1584
[30.]
R.F. Taylor, H. Gaya, D.W. Empey.
A new approach to the treatment of Xanthomonas maltophilia respiratory infection in patients with cystic fibrosis.
Respir Med, 92 (1998), pp. 363-364
[31.]
L.E. Kurlandsky, R.C. Fader.
In vitro activity of minocycline against respiratory pathogens from patients with cystic fibrosis.
Pediatr Pulmunol, 29 (2000), pp. 210-212
[32.]
L. Zhang, L. Xian-Zhi, K. Poole.
Multiple antibiotic resistance in Stenotrophomonas maltophilia: involvement of a multidrug efflux system.
Antimicrob Agents Chemother, 44 (2000), pp. 287-293
[33.]
T. Lambert, M.C. Ploy, F. Denis, P. Courvalin.
Characterization of the chromosomal aac(6')-Iz gene of Stenothrophomonas malthophilia.
Antimicrob Agents Chemother, 43 (1999), pp. 2366-2371
[34.]
P. Vandame, E. Mahenthiralingam, B. Holmes, T. Coenye, B. Hoste, P. De Vos, et al.
Identification and population structure of Burkhokderia stabilis sp. (formerly Burkholderia cepacia genovar IV).
J Clin Microbiol, 37 (2000), pp. 1042-1047
[35.]
T. Coenye, J.J. LiPuma, D. Henry, B. Hoste, K. Vandemeulebroecke, M. Gillis, et al.
Burkholderia cepacia genovar VI. a new member of the Burkholderia cepacia complex isolated from cystic fibrosis patients.
Int J Syst Evol Microbiol, 51 (2001), pp. 271-279
[36.]
S. Bonacorsi, F. Fitoussi, S. Lhopital, E. Bingen.
Comparative in vitro activities of meropenem, imipenem, temocillin, piperacillin, and ceftazidime in combination with tobramycin, rifampin, or ciprofloxacin against Burkholderia cepacia isolates from patients with cystic fibrosis.
Antimicrob Agents Chemother, 43 (1999), pp. 213-217
[37.]
I.A. Baxter, P.A. Lambert.
Isolation and partial purification of a carbapenem- hydrolysing metallo-beta-lactamase from Pseudomonas cepacia.
FEMS Microbiol Lett, 122 (1994), pp. 251-256
[38.]
S. Bonarcosi, F. Fitoussi, S. Lhopital, E. Bingen.
Comparative in vitro activities of meropenem, imipenem, temocillin, piperacillin, and ceftazidime in combination with tobramycin, rifampim, or ciprofloxacin against Burkholderia cepacia isolates from cystic fibrosis patients.
Antimicrob Agents Chemother, 43 (1999), pp. 213-217
[39.]
J.L. Burns, L. Saiman.
Burkholderia cepacia infections in patients with cystic fibrosis.
Pediatr Infect Dis J, 18 (1999), pp. 155-156
[40.]
D. Decre, G. Arlet, E. Bergogne-Berezin, A. Philippon.
Identification of a carbenicillin-hydrolyzing beta-lactamase in Alcaligenes denitrificans subsp. xylosoxydans.
Antimicrob Agents Chemother, 39 (1995), pp. 771-774
[41.]
R.J. Fass, J. Barnishan, M.C. Solomon, L.W. Ayers.
In vitro activities of quinolones, beta-lactams, tobramycin, and trimethoprim-sulfamethoxazole against nonfermentative gram-negative bacilli.
Antimicrob Agents Chemother, 40 (1996), pp. 1412-1418
[42.]
F. Ratjen, G. Comes, K. Paul, H. Posselt, T. Wagner, K. Harms.
Effect of continuous antistaphylococcal therapy on the rate of P. aeruginosa acquisition in patients with cystic fibrosis.
Pediatr Pulmonol, 31 (2001), pp. 13-16
[43.]
R. Givney, A. Vickery, A. Holliday, M. Pegler, R. Benn.
Methicillinresistant Staphylococcus aureus in a cystic fibrosis unit.
J Hosp Infect, 35 (1997), pp. 27-36
[44.]
S.R. Thomas, K.M. Gyi, H. Gaya, M.E. Hodson.
Methicillin resistant Staphylococcus aureus: impact at a national cystic fibrosis center.
J Hosp Epidemiol, 40 (1998), pp. 203-209
[45.]
F. Ratgen.
Changes in strategies for optimal antibacterial therapy in cystic fibrosis.
Int J Antimicrob Agents, 17 (2001), pp. 93-96
[46.]
S. Ballestero, H. Escobar, R. Villaverde, P. Negredo, M. Elia, M. Ojeda- Vargas, et al.
Microbiological parameters and clinical evolution in cystic fibrosis.
Clinical ecology of cystic fibrosis, pp. 55-62
[47.]
J.L. Burns, J. Emerson, J.R. Stapp, D.L. Yim, J. Krzewinski, L. Louden, et al.
Microbiology of sputum from patients at cystic fibrosis centers in the United States.
Clin Infect Dis, 27 (1998), pp. 158-163
[48.]
A. Ferrer Marcelles, P. Bellver Moreira, N. Cobos Barroso, S. Liñan Cortes, G. Codina Grau, F. Fernández Pérez.
Fibrosis quística: estudio microbiológico durante un período de 8 años.
Arch Bronconeumol, 31 (1995), pp. 494-500
[49.]
S. Valdezate, A. Vindel, L. Maiz, F. Baquero, H. Escobar, R. Cantón.
Persistence and variability of Stenotrophomonas maltophilia in cystic fibrosis patients, Madrid, 1991-1998.
Emerg Infect Dis, 7 (2001), pp. 113-122
[50.]
C.A. Demko, R.C. Stern, C.F. Doershuk.
Stenotrophomonas maltophilia in cystic fibrosis: incidence and prevalence.
Pediatr Pulmonol, 25 (1998), pp. 304-308
[51.]
M. Denton.
Stenotrophomonas maltophilia an emerging problem in cystic fibrosis patients.
Rev Med Microbiol, 8 (1997), pp. 15-19
[52.]
I. Talmaciu, L. Varlotta, J. Mortensen, D.V. Schidlow.
Risk factors for emergence of S. maltophilia in cystic fibrosis.
Pediatr Pulmonol, 30 (2000), pp. 10-15
[53.]
K. Mundhi, F.P. Edenborough, L. Gumery, S. O'Hickey, E.G. Smith, D.L. Smith, et al.
Outcome for patients colonized with Burkholderia cepacia in a Birmingham adult cystic fibrosis clinic at the end of an epidemic.
Thorax, 51 (1996), pp. 374-377
[54.]
D.D. Frangolias, E. Mahenthiralingam, S. Rae, J.M. Raboud, A.G. Davidson, R. Wittmann, et al.
Burkholderia cepacia in cystic fibrosis: variable disease course.
Am J Crit Care Med, 160 (1999), pp. 1572-1577
[55.]
C. Chaparro, J. Maurer, C. Gutiérrez, M. Krajden, C. Chan, T. Winton, et al.
Infections with Burkholderia cepacia in cystic fibrosis: outcome following transplantation.
Am J Respir Crit Care Med, 163 (2001), pp. 43-48
[56.]
H. Peltroche-Llacsahuanga, G. Haase, H. Kentrup.
Persistent airway colonization with Alcaligenes xylosoxydans in two brothers with cystic fibrosis.
Eur J Clin Microbiol Infect Dis, 17 (1998), pp. 132-134
[57.]
L. Máiz, F. Baranda, R. Coll, C. Prados, M. Vendrell, A. Escribano, et al.
Normativa del diagnóstico y tratamiento de la afectación respiratoria en la fibrosis quística.
Arch Bronconeumol, 37 (2001), pp. 316-324
[58.]
D. Banerjee, D. Stableforth.
The treatment of respiratory pseudomonas infection in cystic fibrosis: what drug which way?.
Drugs, 60 (2000), pp. 1053-1064
[59.]
G. Doring, S.P. Conway, H.G. Heijerman, M.E. Hodson, N. Hoiby, A. Smyth, et al.
Antibiotic therapy agains Pseudomonas aeruginosa in cystic fibrosis: a European consensus.
Eur Respir J, 16 (2000), pp. 749-767
[60.]
A. Escribano Montaner.
Diagnóstico y tratamiento de la exacerbación infecciosa en la fibrosis quística.
Arch Bronconeumol, 36 (2000), pp. 525-532
[61.]
M. Nir, S. Lanug, H.K. Johansen, C. Koch.
Long-term survival and nutritional data in patients with cystic fibrosis treated in a Danish center.
Thorax, 51 (1996), pp. 1023-1027
[62.]
L. Maiz, R. Cantón, N. Mir, F. Baquero, H. Escobar.
Aerosolized vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infection in cystic fibrosis.
Pediatr Pulmonol, 26 (1998), pp. 287-289
[63.]
S.K. Firdkin.
Vancomycin-intermediate and -resistant Staphylococcus aureus: what the infectious disease specialist needs to know.
Clin Infect Dis, 32 (2001), pp. 108-115
[64.]
G.E. Stein.
Pharmacokinetics and pharmacodynamics of newer fluoroquinolones.
Clin Infect Dis, 23 (1996), pp. S19-S24
[65.]
L. Mooney, K.G. Kerr, M. Denton.
Survival of Stenotrophomonas maltophila following exposure to concentrations of tobramycin used in aerosolized therapy for cystic fibrosis patients.
Int J Antimicrob Agents, 17 (2001), pp. 63-66
[66.]
L. Saiman.
Microbiology and infectious diseases in cystic fibrosis,
[67.]
B.W. Ramsey, K.R. Wentz, A.L. Smith, M. Richardson, J. Williams-Warren, D.L. Hedges, et al.
Predictive value of oropharyngeal cultures for identifying lower airway bacteria in cystic fibrosis patients.
Am Rev Respir Dis, 14 (1991), pp. 331-337
[68.]
P. Gilligan.
Report on the consensus document for microbiology and infectious diseases in cystic fibrosis.
Clin Microbiol Newsletter, 18 (1996), pp. 83-87
[69.]
C. Van Pelt, C.M. Verduin, W.H.F. Goessens, M.C. Vos, B. Tummler, C. Segonds, et al.
Identification of Burkholeria cepacia spp. in the clinical microbiology laboratory: comparison of conventional and molecular methods.
J Clin Microbiol, 37 (1999), pp. 2158-2164
[70.]
Henry DA, Campbell ME, LiPuma JJ, Speert DP. Identification of Burkholderia cepacia isolates from patients with cystic fibrosis and use of a simple new selective medium. J Clin Microbiol
Copyright © 2002. Sociedad Española de Neumología y Cirugía Torácica
